Comparison of Pain of Conventional to Buffered Local Anesthesia During Injection in Pediatric Dental Patients

NCT ID: NCT01622296

Last Updated: 2014-03-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-04-30
• Study Completion Date: 2013-07-31

Brief Summary

The purpose of this study is to determine the effectiveness of buffered local anesthesia injections to numb the gums and teeth during dental treatment. Adjusting the pH of lidocaine with sodium bicarbonate may reduce the pain of injection for both adults and children. In this study, the investigators will compare two local anesthetic preparations, a buffered anesthetic and the conventionally available anesthetic, for pain upon injection.

Hypothesis: Anesthetic buffered to physiologic pH will result in a less painful injection compared to the acidic alternative used in most dental offices. This can be demonstrated by comparing two local anesthetic preparations, a buffered anesthetic and the conventionally available anesthetic, for pain upon injection.

Detailed Description

Local anesthesia is an essential procedure in the comprehensive treatment of pediatric patients. In the treatment of subjects with dental disease and infection, local anesthesia is commonly required when performing operative procedures. The use of local anesthesia serves two main purposes: (i) enables the patient to remain free of discomfort during the sometimes painful procedure and (ii) permits the practitioner to complete the procedure without fear of hurting the patient which might otherwise impede the practitioner's ability to provide comprehensive care. However, patients are often fearful of local anesthesia because traditional preparations of local anesthesia are acidic and can be painful. Thus, an important advance in the areas of subject management and pain control during operative procedures would be a preparation of local anesthesia that significantly reduced the pain upon injection. A 2010 Cochrane Review found that adjusting the pH of lidocaine with sodium bicarbonate reduced the pain of injection for both adults and children. In this study, we will compare two local anesthetic preparations, a buffered anesthetic and the conventionally available anesthetic, for pain upon injection.

The study will test a local anesthetic buffering system, the Onset system, an FDA Class 1 compounding device manufactured by Onpharma Inc. It is a simple and portable local anesthesia buffering system that compounds anesthetic solution and 8.4% sodium bicarbonate neutralizing additive solution in a precise manner that brings the anesthetic solution up to human physiologic pH. Commercially available local anesthetics have a low pH to allow for prolonged shelf life, and to keep the anesthetic molecules in solution. The combination of a buffering sodium bicarbonate agent and local anesthetic has been reported to result in pain-free injections for both adults and children. The neutralizing additive solution is a sterile, nonpyrogenic, solution of sodium bicarbonate (NaHCO3) in water. pH is adjusted with carbon dioxide. Sodium Bicarbonate Inj., 8.4% USP Neutralizing Additive Solution (NDC Code 509-100-03) and Lidocaine w/ Epinephrine are compatible. Sodium bicarbonate is used in medicine and dentistry as regularly as saline, and pre-dates the FDA. It is commercially available and currently being used by health professionals in the U.S.A.

The local anesthetic used in the study will be 2% lidocaine with 1:100,000 ppm epinephrine, part of the amide family of local anesthetics. It has been widely used in dentistry and medicine and has long-standing proven records of safety.

Conditions

Pain

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: DOUBLE

Study Groups

Sodium Bicarbonate with Lidocaine

Group Type: ACTIVE_COMPARATOR

Sodium bicarbonate

Intervention Type: DRUG

8.4% neutralizing solution

Lidocaine with no buffer

Group Type: PLACEBO_COMPARATOR

Lidocaine

Intervention Type: DRUG

2% lidocaine with 1:100,000 ppm epinephrine

Interventions

Sodium bicarbonate

8.4% neutralizing solution

Intervention Type: DRUG

Lidocaine

2% lidocaine with 1:100,000 ppm epinephrine

Intervention Type: DRUG

Other Intervention Names

Sodium Bicarbonate Inj., 8.4% USP Neutralizing Additive Solution (NDC Code 509-100-03); 2% lidocaine (Brand name: Xylocaine) with 1:100,000 ppm epinephrine, part of the amide family of local anesthetics

Eligibility Criteria

Inclusion Criteria

• Give written, informed consent (both the subject and the legal guardian)
• Be 9-12 years of age
• Be able to comprehend the visual analog scale (instructions given to ascertain this)
• Be able to comprehend the verbal rating scale (instructions given to ascertain this)
• In the opinion of the investigator, be a subject who can be expected to comply with the protocol
• Present moderate mandibular dental disease bilaterally
• Have 4 to 7 natural teeth (with at least one posterior tooth) present in each mandibular quadrant with moderate dental disease on at least one tooth
• Be willing to attend the clinic for 3 or more appointments

Exclusion Criteria

• Antibiotic premedication requirement
• A history of allergy, sensitivity, or any other form of adverse reactions to local anesthetics of the amide type, or epinephrine
• A history of specific systemic illness that would preclude administration of a local anesthetic or vasoconstrictor (epinephrine) (e.g. liver , renal, cardiovascular diseases, blood dyscrasias, psychiatric disorders, etc.)
• A history of systemic illness that would interfere with healing response (e.g. liver disease, blood dyscrasias, uncontrolled diabetes, etc.)
• Current systemic medication that interferes with healing response
• Current systemic medication which contraindicates the use of local anesthetics or epinephrine
• Pregnant or lactating females (contradicts the use of local anesthetic in non-emergency type dental procedures)
• Current alcohol or drug abuse
• Received an anesthetic, analgesic or sedative within 24 hours prior to the therapy appointments
• Acute infections or conditions in the oral cavity requiring immediate treatment
• Participation in a clinical study of an investigational drug within the previous 4 weeks
• Previous enrollment in the present study

• Minimum Eligible Age: 9 Years
• Maximum Eligible Age: 12 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of California, San Francisco

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Susan Tavana, DDS

Role: PRINCIPAL_INVESTIGATOR

University of Caifornia, San Francisco

Peter Loomer, DDS, PhD

Role: STUDY_CHAIR

University of California, San Francisco

Locations

University of California, San Francisco

San Francisco, California, United States

Countries

United States

References

Milgrom P, Coldwell SE, Getz T, Weinstein P, Ramsay DS. Four dimensions of fear of dental injections. J Am Dent Assoc. 1997 Jun;128(6):756-66. doi: 10.14219/jada.archive.1997.0301.

Reference Type: BACKGROUND

PMID: 9188235 (View on PubMed)

Cepeda MS, Tzortzopoulou A, Thackrey M, Hudcova J, Arora Gandhi P, Schumann R. Adjusting the pH of lidocaine for reducing pain on injection. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD006581. doi: 10.1002/14651858.CD006581.pub2.

Reference Type: BACKGROUND

PMID: 21154371 (View on PubMed)

von Baeyer CL. Children's self-report of pain intensity: what we know, where we are headed. Pain Res Manag. 2009 Jan-Feb;14(1):39-45. doi: 10.1155/2009/259759.

Reference Type: BACKGROUND

PMID: 19262915 (View on PubMed)

Other Identifiers

1107214

Identifier Type: -

Identifier Source: org_study_id